AstraZeneca shares sink 7% on report of historic $400 billion merger talks with Bristol Myers Squibb

AstraZeneca is considering a merger with Bristol Myers Squibb, potentially valued at $400 billion. Talks have occurred for several months, but no formal agreement is expected soon. AstraZeneca shares fell 7% on news of the merger discussions, while Bristol Myers stocks rose by 3.8%. Source: Read the original article on www.livemint.com